| Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia | 05/30 16:05 | globenewswire.com |
| 2 Potentially High-Reward Growth Stocks to Buy Right Now | 05/29 08:45 | fool.com |
| Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study | 05/22 12:25 | zacks.com |
| Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia | 05/20 16:05 | globenewswire.com |
| Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results | 05/09 07:00 | globenewswire.com |
| Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development | 03/14 16:05 | globenewswire.com |
| Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia | 03/11 16:05 | globenewswire.com |
| Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference | 03/06 16:05 | globenewswire.com |
| Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | 02/16 16:20 | globenewswire.com |
| Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock | 02/14 06:15 | globenewswire.com |